India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business
You may also be interested in...ï»¿
Clinical trial approvals in India have declined sharply in recent months but that has not held back companies active in the sector â€“ both local and global â€“ from making acquisitions. The trend may continue as a few more deals are said to be on the anvil.